E

ELEVAI Labs Inc
NASDAQ:ELAB

Watchlist Manager
ELEVAI Labs Inc
NASDAQ:ELAB
Watchlist
Price: 0.4025 USD -71.65% Market Closed
Market Cap: 4.8m USD

ELEVAI Labs Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ELEVAI Labs Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
E
ELEVAI Labs Inc
NASDAQ:ELAB
Cash from Operating Activities
-$5.5m
CAGR 3-Years
-227%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kenvue Inc
NYSE:KVUE
Cash from Operating Activities
$1.8B
CAGR 3-Years
74%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Safety Shot Inc
NASDAQ:SHOT
Cash from Operating Activities
-$19.1m
CAGR 3-Years
-36%
CAGR 5-Years
-94%
CAGR 10-Years
N/A
Horizon Kinetics Holding Corp
OTC:HKHC
Cash from Operating Activities
$11.8m
CAGR 3-Years
N/A
CAGR 5-Years
77%
CAGR 10-Years
16%
Bonk Inc
NASDAQ:BNKK
Cash from Operating Activities
-$19.1m
CAGR 3-Years
-36%
CAGR 5-Years
-94%
CAGR 10-Years
N/A
F
Functional Brands Inc
NASDAQ:MEHA
Cash from Operating Activities
$2k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ELEVAI Labs Inc
Glance View

Market Cap
4.8m USD
Industry
Consumer products

ELEVAI Labs Inc is a US-based company operating in Personal Care Products industry. The company is headquartered in Newport Beach, California. The company went IPO on 2023-11-21. Elevai Labs, Inc. is a physician-dispensed skincare company. The firm conducts research and development to advance science-driven topical skincare that complements the medical aesthetics industry. The company produces and commercializes topical skincare products that contain its proprietary stem cell derived Elevai Exosomes designed to enhance the appearance of skin. Its Precision Regenerative Exosome Technology (PREx) biotechnology process yields exosome lots from human umbilical cord-derived mesenchymal stem cells (hUMSC) for its specialty physician-dispensed skincare products. The company has integrated the use of stem cell exosomes into its initial product line: Elevai Post Treatment E-Series. The E-Series comprises two post-skincare procedure care products that target the face and neck, and upper chest regions. Its products include Empower and Enfinity serums. Empower is its after-treatment topical product that supports the appearance of healthy skin and promotes an even toned complexion.

ELAB Intrinsic Value
Not Available
E

See Also

What is ELEVAI Labs Inc's Cash from Operating Activities?
Cash from Operating Activities
-4.6m USD

Based on the financial report for Dec 31, 2023, ELEVAI Labs Inc's Cash from Operating Activities amounts to -4.6m USD.

What is ELEVAI Labs Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-227%

Over the last year, the Cash from Operating Activities growth was -187%. The average annual Cash from Operating Activities growth rates for ELEVAI Labs Inc have been -227% over the past three years .

Back to Top